Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

The Dana-Farber Cancer Institute (DFCI) Childhood ALL Consortium Protocol 95-01 was designed to minimize therapy-related morbidity for children with newly diagnosed ALL without compromising efficacy. Patients participated in randomized comparisons of (1) doxorubicin given with or without dexrazoxane...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Moghrabi, Albert, Levy, Donna E., Asselin, Barbara, Barr, Ronald, Clavell, Luis, Hurwitz, Craig, Samson, Yvan, Schorin, Marshall, Dalton, Virginia K., Lipshultz, Steven E., Neuberg, Donna S., Gelber, Richard D., Cohen, Harvey J., Sallan, Stephen E., Silverman, Lewis B.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2007
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785142/
https://ncbi.nlm.nih.gov/pubmed/17003366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-027714
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы